english.prescrire.org > Prescrire International > N°154 - November 2014

n°154

November 2014

Issue Contents
Editorial

Free  Informed screening

p.256
First, do no harm

New Products


Pomalidomide (New Drug)

p.257-259
A last-line treatment option for multiple myeloma

INN common stem: -antrone

p.259

Free  Artesunate

p.260
The standard intravenous treatment for severe attacks of malaria

Ingenol mebutate (New Drug)

p.261
An unjustified irritant effect in discrete actinic keratosis

Dolutegravir (New Drug)

p.262-263
The third HIV integrase inhibitor: one more option

Adverse Effects


Telithromycin: review of adverse effects

p.264-266
No justification to keep it on the market

Gabapentin and pregabalin: sometimes serious hepatic and haematological toxicity

p.267
Potentially fatal

Pazopanib: pericardial effusion

p.268
Apparently common with this class of drugs

Interferon alfa: retinal detachment

p.268
Informing patients on interferon

SSRI antidepressants in utero: pulmonary hypertension

p.268
Second half of pregnancy

Interferon alfa: hyperpigmentation

p.268
Direct sunlight should be avoided

Reviews


Type 2 diabetes and metformin

p.269-272
First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects

Acetazolamide and prevention of acute mountain sickness

p.273
Favourable harm-benefit balance

Outlook


Free  Determining the harm-benefit balance of an intervention: for each patient

p.274-277
A central part of decision-making

Dare to refuse the exorbitant price of Sovaldi°

p.278
Blatant profiteering

Resistance to the rise of the tablet in France

p.279
A piece of history

Masthead


Free  Masthead

p.254

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe